Effective July 20, 2017, minoxidil, when sold in preparations for topical use in adults in concentrations of 5% or less, has been granted unscheduled status. Minoxidil is a medication used to treat hair loss.
The National Association of Pharmacy Regulatory Authorities (NAPRA) Executive Committee approved the Interim Recommendation, made by the National Drug Scheduling Advisory Committee, following a 30-day review period. The National Drug Schedules will be revised to reflect this change.
